{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T17:30:45Z","timestamp":1787333445340,"version":"build-2736575974"},"reference-count":198,"publisher":"Elsevier","isbn-type":[{"value":"9780443470547","type":"print"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/bs.ai.2026.06.003","type":"book-chapter","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T20:41:53Z","timestamp":1782160913000},"page":"247-281","source":"Crossref","is-referenced-by-count":0,"title":["Microglial advances in Parkinson\u2019s disease"],"prefix":"10.1016","author":[{"given":"Manuel","family":"Debasa-Mouce","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Ouro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"De Leon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelly","family":"Gulkarov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison B.","family":"Reiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Bougea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/bs.ai.2026.06.003_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.105185","article-title":"Oligomeric \u03b1-Syn and SNARE complex proteins in peripheral extracellular vesicles of neural origin are biomarkers for Parkinson\u2019s disease","volume":"148","author":"Agliardi","year":"2021","journal-title":"Neurobiology of Disease"},{"issue":"2","key":"10.1016\/bs.ai.2026.06.003_bib2","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3906\/sag-2008-253","article-title":"Dopamine transporter SPECT imaging in Parkinson\u2019s disease and parkinsoniandisorders","volume":"51","author":"Akdemir","year":"2021","journal-title":"Turkish Journal of Medical Sciences"},{"issue":"4","key":"10.1016\/bs.ai.2026.06.003_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci15040379","article-title":"TREM 2 in Parkinson\u2019s disease: A promising candidate gene for disease susceptibility and progression","volume":"15","author":"Alonge","year":"2025","journal-title":"Brain Sciences"},{"issue":"1","key":"10.1016\/bs.ai.2026.06.003_bib4","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-023-02830-w","article-title":"Pharmacologic inhibition of NLRP3 reduces the levels of \u03b1-synuclein and protects dopaminergic neurons in a model of Parkinson\u2019s disease","volume":"20","author":"Amo-Aparicio","year":"2023","journal-title":"Journal of Neuroinflammation"},{"issue":"1","key":"10.1016\/bs.ai.2026.06.003_bib5","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1093\/brain\/awaa365","article-title":"Dopaminergic imaging and clinical predictors for phenoconversion of REM sleep behaviour disorder","volume":"144","author":"Arnaldi","year":"2021","journal-title":"Brain: A Journal of Neurology"},{"issue":"10","key":"10.1016\/bs.ai.2026.06.003_bib6","first-page":"8","article-title":"What do microglia really do in healthy adult brain?","volume":"8","author":"Augusto-Oliveira","year":"2019","journal-title":"Cells 2019"},{"issue":"1","key":"10.1016\/bs.ai.2026.06.003_bib7","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1038\/s41467-023-37454-4","article-title":"Glucocerebrosidase is imported into mitochondria and preserves complex I integrity and energy metabolism","volume":"14","author":"Baden","year":"2023","journal-title":"Nature Communications"},{"issue":"1","key":"10.1016\/bs.ai.2026.06.003_bib8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/ene.14108","article-title":"Parkinson disease","volume":"27","author":"Balestrino","year":"2020","journal-title":"European Journal of Neurology"},{"key":"10.1016\/bs.ai.2026.06.003_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2021.629279","article-title":"Validation of induced microglia-like cells (iMG cells) for future studies of brain diseases","volume":"15","author":"Banerjee","year":"2021","journal-title":"Frontiers in Cellular Neuroscience"},{"issue":"5","key":"10.1016\/bs.ai.2026.06.003_bib10","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.mri.2015.02.021","article-title":"Quantifying brain iron deposition in patients with Parkinson\u2019s disease using quantitative susceptibility mapping, R2 and R2\u204e","volume":"33","author":"Barbosa","year":"2015","journal-title":"Magnetic Resonance Imaging"},{"issue":"1","key":"10.1016\/bs.ai.2026.06.003_bib11","doi-asserted-by":"crossref","DOI":"10.1186\/s40478-021-01175-w","article-title":"Streamlined alpha-synuclein RT-QuIC assay for various biospecimens in Parkinson\u2019s disease and dementia with Lewy bodies","volume":"9","author":"Bargar","year":"2021","journal-title":"Acta Neuropathologica Communications"},{"issue":"1","key":"10.1016\/bs.ai.2026.06.003_bib12","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41531-022-00384-x","article-title":"Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson\u2019s disease","volume":"8","author":"Batzu","year":"2022","journal-title":"Npj Parkinson\u2019s Disease"},{"key":"10.1016\/bs.ai.2026.06.003_bib13","doi-asserted-by":"crossref","first-page":"48","DOI":"10.7150\/thno\/v01p0048","article-title":"PET imaging of integrin \u03b1V\u03b23 expression","volume":"1","author":"Beer","year":"2011","journal-title":"Theranostics"},{"issue":"5","key":"10.1016\/bs.ai.2026.06.003_bib14","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S1474-4422(23)00124-2","article-title":"\u03b1-Synuclein seed amplification and its uses in Parkinson\u2019s disease","volume":"22","author":"Berg","year":"2023","journal-title":"The Lancet Neurology"},{"issue":"4","key":"10.1016\/bs.ai.2026.06.003_bib15","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/jnc.15516","article-title":"The role of neuroimaging in Parkinson\u2019s disease","volume":"159","author":"Bidesi","year":"2021","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/bs.ai.2026.06.003_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2025.110701","article-title":"N-terminal KTKEGV motif lysine residues of \u03b1-Synuclein are critical for TLR2 interaction and activation","volume":"776","author":"Bisht","year":"2026","journal-title":"Archives of Biochemistry and Biophysics"},{"key":"10.1016\/bs.ai.2026.06.003_bib17","article-title":"LRRK2-mutant microglia trigger dopaminergic neurodegeneration when activated by neuromelanin","author":"Blasco-Agell","year":"2024","journal-title":"BioRxiv"},{"issue":"2","key":"10.1016\/bs.ai.2026.06.003_bib18","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson\u2019s disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiology of Aging"},{"issue":"1","key":"10.1016\/bs.ai.2026.06.003_bib19","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3390\/ijms22010194","article-title":"Distinction of microglia and macrophages in glioblastoma: Close relatives, different tasks?","volume":"22","author":"Brandenburg","year":"2020","journal-title":"International Journal of Molecular Sciences"},{"issue":"1","key":"10.1016\/bs.ai.2026.06.003_bib20","doi-asserted-by":"crossref","DOI":"10.1186\/s40478-021-01276-6","article-title":"Association between CSF alpha-synuclein seeding activity and genetic status in Parkinson\u2019s disease and dementia with Lewy bodies","volume":"9","author":"Brockmann","year":"2021","journal-title":"Acta Neuropathologica Communications"},{"issue":"2","key":"10.1016\/bs.ai.2026.06.003_bib21","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/mds.28909","article-title":"Age-adjusted serum neurofilament predicts cognitive decline in Parkinson\u2019s disease (MARK-PD)","volume":"37","author":"Buhmann","year":"2022","journal-title":"Movement Disorders"},{"key":"10.1016\/bs.ai.2026.06.003_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2025.102282","article-title":"NLRP3 inhibition by VTX3232 tempers inflammation resulting in reduced body weight, hyperglycemia, and hepatic steatosis in obese male mice","volume":"103","author":"Bultinck","year":"2026","journal-title":"Molecular Metabolism"},{"issue":"1","key":"10.1016\/bs.ai.2026.06.003_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-026-08557-9","article-title":"Complement receptor 3 (CR3)-dependent microglial synapse elimination drives Parkinson\u2019s disease pathogenesis in systemic inflammation","volume":"17","author":"Cai","year":"2026","journal-title":"Cell Death & Disease"},{"issue":"10","key":"10.1016\/bs.ai.2026.06.003_bib24","doi-asserted-by":"crossref","first-page":"6503","DOI":"10.21037\/qims-23-87","article-title":"Diagnostic value of combined magnetic resonance imaging techniques in the evaluation of Parkinson disease","volume":"13","author":"Cao","year":"2023","journal-title":"Quantitative Imaging in Medicine and Surgery"},{"issue":"1","key":"10.1016\/bs.ai.2026.06.003_bib25","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41531-025-01249-9","article-title":"Microglial low-affinity Fc\u03b3R mediates the phagocytic elimination of dopaminergic neurons in Parkinson\u2019s disease degeneration","volume":"12","author":"Casanova","year":"2026","journal-title":"Npj Parkinson\u2019s Disease"},{"issue":"5","key":"10.1016\/bs.ai.2026.06.003_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175674","article-title":"Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease","volume":"12","author":"Caspell-Garcia","year":"2017","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/bs.ai.2026.06.003_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cells10030604","article-title":"Cytokine profile in plasma extracellular vesicles of Parkinson\u2019s disease and the association with cognitive function","volume":"10","author":"Chan","year":"2021","journal-title":"Cells"},{"issue":"3","key":"10.1016\/bs.ai.2026.06.003_bib28","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41588-021-00785-3","article-title":"Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture","volume":"53","author":"Chia","year":"2021","journal-title":"Nature Genetics"},{"issue":"5","key":"10.1016\/bs.ai.2026.06.003_bib29","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s43440-020-00120-3","article-title":"Neurotrophic factors for disease-modifying treatments of Parkinson\u2019s disease: Gaps between basic science and clinical studies","volume":"72","author":"Chmielarz","year":"2020","journal-title":"Pharmacological Reports: PR"},{"issue":"3","key":"10.1016\/bs.ai.2026.06.003_bib30","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1007\/s00330-020-07240-7","article-title":"Diagnostic performance of neuromelanin-sensitive magnetic resonance imaging for patients with Parkinson\u2019s disease and factor analysis for its heterogeneity: A systematic review and meta-analysis","volume":"31","author":"Cho","year":"2021","journal-title":"European Radiology"},{"issue":"1","key":"10.1016\/bs.ai.2026.06.003_bib31","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3390\/brainsci16010110","article-title":"Neuroimaging and pathology biomarkers in Parkinson\u2019s disease and Parkinsonism","volume":"16","author":"Cilia","year":"2026","journal-title":"Brain Sciences"},{"issue":"10","key":"10.1016\/bs.ai.2026.06.003_bib32","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1002\/mds.30307","article-title":"Anti-neuroinflammatory and anti-inflammatory effects of the NLRP3 inhibitor NT-0796 in subjects with Parkinson\u2019s disease","volume":"40","author":"Clarke","year":"2025","journal-title":"Movement Disorders: Official Journal of the Movement Disorder Society"},{"key":"10.1016\/bs.ai.2026.06.003_bib33","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1146\/annurev-immunol-051116-052358","article-title":"Microglia function in the central nervous system during health and neurodegeneration","volume":"35","author":"Colonna","year":"2017","journal-title":"Annual Review of Immunology"},{"issue":"2","key":"10.1016\/bs.ai.2026.06.003_bib34","doi-asserted-by":"crossref","DOI":"10.1136\/bmjno-2023-000535","article-title":"Ambroxol as a disease-modifying treatment to reduce the risk of cognitive impairment in GBA-associated Parkinson\u2019s disease: A multicentre, randomised, double-blind, placebo-controlled, phase II trial. The AMBITIOUS study protocol","volume":"5","author":"Colucci","year":"2023","journal-title":"BMJ Neurology Open"},{"issue":"6","key":"10.1016\/bs.ai.2026.06.003_bib35","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1053\/j.sult.2020.08.006","article-title":"PET and SPECT imaging of the brain: History, technical considerations, applications, and radiotracers","volume":"41","author":"Davis","year":"2020","journal-title":"Seminars in Ultrasound, CT and MRI"},{"issue":"8","key":"10.1016\/bs.ai.2026.06.003_bib36","first-page":"1786","article-title":"Role of functional neuroimaging with 123I-MIBG and 123I-FP-CIT in De Novo Parkinson\u2019s disease: A multicenter study","volume":"13","author":"De Feo","year":"2023","journal-title":"Life (Chicago, Ill.: 1978)"},{"issue":"1","key":"10.1016\/bs.ai.2026.06.003_bib37","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-41122-y","article-title":"CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer\u2019s disease","volume":"14","author":"del Campo","year":"2023","journal-title":"Nature Communications"},{"issue":"3","key":"10.1016\/bs.ai.2026.06.003_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24032477","article-title":"The Interplay between \u03b1-synuclein and microglia in \u03b1-synucleinopathies","volume":"24","author":"Deyell","year":"2023","journal-title":"International Journal of Molecular Sciences"},{"issue":"1","key":"10.1016\/bs.ai.2026.06.003_bib39","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/mds.26312","article-title":"Gray and white matter imaging: A biomarker for cognitive impairment in early Parkinson\u2019s disease?","volume":"31","author":"Duncan","year":"2016","journal-title":"Movement Disorders: Official Journal of the Movement Disorder Society"},{"issue":"1","key":"10.1016\/bs.ai.2026.06.003_bib40","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.expneurol.2008.01.026","article-title":"AAV2-mediated gene transfer of GDNF to the striatum of MPTP monkeys enhances the survival and outgrowth of co-implanted fetal dopamine neurons","volume":"211","author":"Elsworth","year":"2008","journal-title":"Experimental Neurology"},{"issue":"3","key":"10.1016\/bs.ai.2026.06.003_bib41","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/glia.22437","article-title":"Toll-like receptor 4 is required for \u03b1-synuclein dependent activation of microglia and astroglia","volume":"61","author":"Fellner","year":"2013","journal-title":"Glia"},{"key":"10.1016\/bs.ai.2026.06.003_bib42","article-title":"Progressive brain atrophy and clinical evolution in Parkinson\u2019s disease","volume":"28","author":"Filippi","year":"2020","journal-title":"NeuroImage: Clinical"},{"issue":"1","key":"10.1016\/bs.ai.2026.06.003_bib43","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/ene.14032","article-title":"The value of cerebrospinal fluid \u03b1-synuclein and the tau\/\u03b1-synuclein ratio for diagnosis of neurodegenerative disorders with Lewy pathology","volume":"27","author":"F\u00f8rland","year":"2020","journal-title":"European Journal of Neurology"},{"issue":"1","key":"10.1016\/bs.ai.2026.06.003_bib44","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41536-020-00106-y","article-title":"Challenges and translational considerations of mesenchymal stem\/stromal cell therapy for Parkinson\u2019s disease","volume":"5","author":"Fri\u010dov\u00e1","year":"2020","journal-title":"Npj Regenerative Medicine"},{"key":"10.1016\/bs.ai.2026.06.003_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.702639","article-title":"Alpha-synuclein as a biomarker of Parkinson\u2019s disease: Good, but not good enough","volume":"13","author":"Ganguly","year":"2021","journal-title":"Frontiers in Aging Neuroscience"},{"issue":"1","key":"10.1016\/bs.ai.2026.06.003_bib46","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41392-023-01588-0","article-title":"Microglia in neurodegenerative diseases: Mechanism and potential therapeutic targets","volume":"8","author":"Gao","year":"2023","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"15","key":"10.1016\/bs.ai.2026.06.003_bib47","doi-asserted-by":"crossref","first-page":"6181","DOI":"10.1523\/JNEUROSCI.23-15-06181.2003","article-title":"Critical role for microglial NADPH oxidase in rotenone-induced degeneration of dopaminergic neurons","volume":"23","author":"Gao","year":"2003","journal-title":"The Journal of Neuroscience: The Official Journal of the Society for Neuroscience"},{"issue":"2","key":"10.1016\/bs.ai.2026.06.003_bib48","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.nbd.2005.08.002","article-title":"In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson\u2019s disease","volume":"21","author":"Gerhard","year":"2006","journal-title":"Neurobiology of Disease"},{"issue":"8","key":"10.1016\/bs.ai.2026.06.003_bib49","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1093\/brain\/awu159","article-title":"Grey matter hypometabolism and atrophy in Parkinson\u2019s disease with cognitive impairment: A two-step process","volume":"137","author":"Gonz\u00e1lez-Redondo","year":"2014","journal-title":"Brain"},{"issue":"5","key":"10.1016\/bs.ai.2026.06.003_bib50","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/mdc3.13710","article-title":"\u03b1-Synuclein seed amplification assays in the diagnosis of synucleinopathies using cerebrospinal fluid-a systematic review and meta-analysis","volume":"10","author":"Grossauer","year":"2023","journal-title":"Movement Disorders Clinical Practice"},{"issue":"1","key":"10.1016\/bs.ai.2026.06.003_bib51","doi-asserted-by":"crossref","DOI":"10.1186\/s40478-018-0508-2","article-title":"Rapid and ultra-sensitive quantitation of disease-associated j\u03b1-synuclein seeds in brain and cerebrospinal fluid by \u03b1Syn RT-QuIC","volume":"6","author":"Groveman","year":"2018","journal-title":"Acta Neuropathologica Communications"},{"key":"10.1016\/bs.ai.2026.06.003_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.815347","article-title":"Microglia polarization from M1 to M2 in neurodegenerative diseases","volume":"14","author":"Guo","year":"2022","journal-title":"Frontiers in Aging Neuroscience"},{"key":"10.1016\/bs.ai.2026.06.003_bib53","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.omtm.2019.11.012","article-title":"Adeno-associated viral vectors in neuroscience research","volume":"17","author":"Haggerty","year":"2020","journal-title":"Molecular Therapy Methods and Clinical Development"},{"issue":"6","key":"10.1016\/bs.ai.2026.06.003_bib54","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/mds.26578","article-title":"Longitudinal measurements of cerebrospinal fluid biomarkers in Parkinson\u2019s disease","volume":"31","author":"Hall","year":"2016","journal-title":"Movement Disorders: Official Journal of the Movement Disorder Society"},{"issue":"1","key":"10.1016\/bs.ai.2026.06.003_bib55","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/mds.27874","article-title":"Targeting the microglial NLRP3 inflammasome and its role in Parkinson\u2019s disease","volume":"35","author":"Haque","year":"2020","journal-title":"Movement Disorders: Official Journal of the Movement Disorder Society"},{"issue":"11","key":"10.1016\/bs.ai.2026.06.003_bib56","doi-asserted-by":"crossref","first-page":"5318","DOI":"10.1039\/D5MD00639B","article-title":"Profile of NT-0527, a brain penetrant NLRP3 Inflammasome inhibitor suitable as an in vivo tool compound for neuroinflammatory disorders","volume":"16","author":"Harrison","year":"2025","journal-title":"RSC Medicinal Chemistry"},{"issue":"10","key":"10.1016\/bs.ai.2026.06.003_bib57","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/s41593-018-0242-x","article-title":"Microglia in neurodegeneration","volume":"21","author":"Hickman","year":"2018","journal-title":"Nature Neuroscience"},{"issue":"2","key":"10.1016\/bs.ai.2026.06.003_bib58","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1474-4422(23)00404-0","article-title":"A biological classification of Parkinson\u2019s disease: The SynNeurGe research diagnostic criteria","volume":"23","author":"H\u00f6glinger","year":"2024","journal-title":"The Lancet Neurology"},{"issue":"8","key":"10.1016\/bs.ai.2026.06.003_bib59","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.7150\/thno.128257","article-title":"Colostrum extracellular vesicles are neuroprotective in models of Parkinson\u2019s disease","volume":"16","author":"Hollingsworth","year":"2026","journal-title":"Theranostics"},{"issue":"10","key":"10.1016\/bs.ai.2026.06.003_bib60","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1093\/brain\/awaa238","article-title":"Brain-first versus body-first Parkinson\u2019s disease: A multimodal imaging case-control study","volume":"143","author":"Horsager","year":"2020","journal-title":"Brain: A Journal of Neurology"},{"issue":"1","key":"10.1016\/bs.ai.2026.06.003_bib61","article-title":"Glucosylceramide in cerebrospinal fluid of patients with GBA-associated and idiopathic Parkinson\u2019s disease enrolled in PPMI","volume":"7","author":"Huh","year":"2021","journal-title":"NPJ Parkinson\u2019s Disease"},{"issue":"3","key":"10.1016\/bs.ai.2026.06.003_bib62","doi-asserted-by":"crossref","first-page":"261","DOI":"10.14802\/jmd.23023","article-title":"GBA1 variants and Parkinson\u2019s disease: Paving the way for targeted therapy","volume":"16","author":"Huh","year":"2023","journal-title":"Journal of Movement Disorders"},{"issue":"4","key":"10.1016\/bs.ai.2026.06.003_bib63","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0282684","article-title":"In vivo detection of substantia nigra and locus coeruleus volume loss in Parkinson\u2019s disease using neuromelanin-sensitive MRI: Replication in two cohorts","volume":"18","author":"Hwang","year":"2023","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/bs.ai.2026.06.003_bib64","first-page":"102","article-title":"The sensitivity and specificity of F-DOPA PET in a movement disorder clinic","volume":"6","author":"Ibrahim","year":"2016","journal-title":"American Journal of Nuclear Medicine and Molecular Imaging"},{"issue":"3","key":"10.1016\/bs.ai.2026.06.003_bib65","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S1474-4422(20)30449-X","article-title":"Detection of \u03b1-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study","volume":"20","author":"Iranzo","year":"2021","journal-title":"The Lancet Neurology"},{"issue":"1","key":"10.1016\/bs.ai.2026.06.003_bib66","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1474-4422(16)30291-5","article-title":"Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: A retrospective analysis","volume":"16","author":"Irwin","year":"2017","journal-title":"The Lancet Neurology"},{"issue":"7","key":"10.1016\/bs.ai.2026.06.003_bib67","doi-asserted-by":"crossref","DOI":"10.3390\/cells12071012","article-title":"Microglia mediated neuroinflammation in Parkinson\u2019s disease","volume":"12","author":"Isik","year":"2023","journal-title":"Cells"},{"issue":"5","key":"10.1016\/bs.ai.2026.06.003_bib68","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/ajh.26131","article-title":"Upgrading the evidence for the use of ambroxol in Gaucher disease and GBA related Parkinson: Investigator initiated registry based on real life data","volume":"96","author":"Istaiti","year":"2021","journal-title":"American Journal of Hematology"},{"issue":"648","key":"10.1016\/bs.ai.2026.06.003_bib69","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abj2658","article-title":"Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson\u2019s disease","volume":"14","author":"Jennings","year":"2022","journal-title":"Science Translational Medicine"},{"key":"10.1016\/bs.ai.2026.06.003_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2020.00198","article-title":"Overview of general and discriminating markers of differential microglia phenotypes","volume":"14","author":"Jurga","year":"2020","journal-title":"Frontiers in Cellular Neuroscience"},{"issue":"6","key":"10.1016\/bs.ai.2026.06.003_bib71","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/ana.25103","article-title":"Striatal dopamine in Parkinson disease: A meta-analysis of imaging studies","volume":"82","author":"Kaasinen","year":"2017","journal-title":"Annals of Neurology"},{"issue":"5","key":"10.1016\/bs.ai.2026.06.003_bib72","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/s41593-022-01061-1","article-title":"Single-cell genomic profiling of human dopamine neurons identifies a population that selectively degenerates in Parkinson\u2019s disease","volume":"25","author":"Kamath","year":"2022","journal-title":"Nature Neuroscience"},{"issue":"10","key":"10.1016\/bs.ai.2026.06.003_bib73","first-page":"1277","article-title":"Association of cerebrospinal fluid \u03b2-amyloid 1-42, T-tau, P-tau181, and \u03b1-synuclein levels with clinical features of drug-naive patients with early Parkinson disease","volume":"70","author":"Kang","year":"2013","journal-title":"JAMA Neurology"},{"issue":"4","key":"10.1016\/bs.ai.2026.06.003_bib74","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/mds.27646","article-title":"Comparative study of cerebrospinal fluid \u03b1-synuclein seeding aggregation assays for diagnosis of Parkinson\u2019s disease","volume":"34","author":"Kang","year":"2019","journal-title":"Movement Disorders: Official Journal of the Movement Disorder Society"},{"issue":"1","key":"10.1016\/bs.ai.2026.06.003_bib75","doi-asserted-by":"crossref","DOI":"10.1177\/1877718X251397277","article-title":"Clinical trial highlights: Dopamine cell-replacement therapies","volume":"16","author":"Kayhanian","year":"2026","journal-title":"Journal of Parkinson\u2019s Disease"},{"issue":"7","key":"10.1016\/bs.ai.2026.06.003_bib76","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.cell.2017.05.018","article-title":"A unique microglia type associated with restricting development of Alzheimer\u2019s disease","volume":"169","author":"Keren-Shaul","year":"2017","journal-title":"Cell"},{"key":"10.1016\/bs.ai.2026.06.003_bib77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2011\/796025","article-title":"Molecular SPECT imaging: An overview","volume":"2011","author":"Khalil","year":"2011","journal-title":"International Journal of Molecular Imaging"},{"key":"10.1016\/bs.ai.2026.06.003_bib78","article-title":"Neuron-released oligomeric \u03b1-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia","volume":"4","author":"Kim","year":"2013","journal-title":"Nature Communications"},{"issue":"5","key":"10.1016\/bs.ai.2026.06.003_bib79","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S2665-9913(20)30065-5","article-title":"Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: An open-label, dose-adaptive, proof-of-concept, phase 2a trial","volume":"2","author":"Kl\u00fcck","year":"2020","journal-title":"The Lancet. Rheumatology"},{"issue":"9","key":"10.1016\/bs.ai.2026.06.003_bib80","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1093\/brain\/awac115","article-title":"Detection of neuron-derived pathological \u03b1-synuclein in blood","volume":"145","author":"Kluge","year":"2022","journal-title":"Brain"},{"key":"10.1016\/bs.ai.2026.06.003_bib81","first-page":"3","article-title":"Parkinson\u2019s disease: Etiology, neuropathology, and pathogenesis","author":"Kouli","year":"2018","journal-title":"Exon Publications"},{"issue":"3","key":"10.1016\/bs.ai.2026.06.003_bib82","doi-asserted-by":"crossref","DOI":"10.1007\/s13346-025-01944-3","article-title":"Polymeric nanoparticle-mediated GBA1 gene therapy is neuroprotective in a preclinical model of Parkinson\u2019s disease","volume":"16","author":"Kwatra","year":"2026","journal-title":"Drug Delivery and Translational Research"},{"issue":"2","key":"10.1016\/bs.ai.2026.06.003_bib83","first-page":"12","article-title":"Update on CSF Biomarkers in Parkinson\u2019s disease","volume":"12","author":"Kwon","year":"2022","journal-title":"Biomolecules 2022"},{"issue":"11","key":"10.1016\/bs.ai.2026.06.003_bib84","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1002\/mds.28706","article-title":"International multicenter analysis of brain structure across clinical stages of Parkinson\u2019s disease","volume":"36","author":"Laansma","year":"2021","journal-title":"Movement Disorders: Official Journal of the Movement Disorder Society"},{"key":"10.1016\/bs.ai.2026.06.003_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuroimage.2022.119454","article-title":"Evaluation of iron overload in nigrosome 1 via quantitative susceptibility mapping as a progression biomarker in prodromal stages of synucleinopathies","volume":"260","author":"Lancione","year":"2022","journal-title":"Neuroimage"},{"issue":"3","key":"10.1016\/bs.ai.2026.06.003_bib86","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/j.neuroimage.2012.05.049","article-title":"Quantitative susceptibility mapping (QSM) as a means to measure brain iron? A post mortem validation study","volume":"62","author":"Langkammer","year":"2012","journal-title":"Neuroimage"},{"issue":"1","key":"10.1016\/bs.ai.2026.06.003_bib87","doi-asserted-by":"crossref","DOI":"10.1186\/s40035-024-00401-4","article-title":"\u03b1-Synuclein oligomers potentiate neuroinflammatory NF-\u03baB activity and induce Cav3.2 calcium signaling in astrocytes","volume":"13","author":"Leandrou","year":"2024","journal-title":"Translational Neurodegeneration"},{"issue":"4","key":"10.1016\/bs.ai.2026.06.003_bib88","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1474-4422(11)70039-4","article-title":"AAV2-GAD gene therapy for advanced Parkinson\u2019s disease: A double-blind, sham-surgery controlled, randomised trial","volume":"10","author":"LeWitt","year":"2011","journal-title":"The Lancet Neurology"},{"issue":"2","key":"10.1016\/bs.ai.2026.06.003_bib89","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-020-2298-2","article-title":"Ferroptosis: Past, present and future","volume":"11","author":"Li","year":"2020","journal-title":"Cell Death & Disease"},{"issue":"5","key":"10.1016\/bs.ai.2026.06.003_bib90","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/ana.24781","article-title":"Specifically neuropathic Gaucher\u2019s mutations accelerate cognitive decline in Parkinson\u2019s","volume":"80","author":"Liu","year":"2016","journal-title":"Annals of Neurology"},{"issue":"1","key":"10.1016\/bs.ai.2026.06.003_bib91","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13024-017-0226-4","article-title":"YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias","volume":"12","author":"Llorens","year":"2017","journal-title":"Molecular Neurodegeneration"},{"issue":"50","key":"10.1016\/bs.ai.2026.06.003_bib92","doi-asserted-by":"crossref","first-page":"32145","DOI":"10.1073\/pnas.2009680117","article-title":"The NLRP3 inflammasome inhibitor OLT1177 rescues cognitive impairment in a mouse model of Alzheimer\u2019s disease","volume":"117","author":"Lonnemann","year":"2020","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"5","key":"10.1016\/bs.ai.2026.06.003_bib93","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s12264-017-0183-5","article-title":"Biomarkers for Parkinson\u2019s disease: Recent advancement","volume":"33","author":"Lotankar","year":"2017","journal-title":"Neuroscience Bulletin"},{"issue":"1","key":"10.1016\/bs.ai.2026.06.003_bib94","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12974-026-03716-3","article-title":"Clinically advanced NLRP3 inhibitor modulates microglial transcriptome and alleviates \u03b1-synuclein-induced progression of parkinsonism","volume":"23","author":"Luque","year":"2026","journal-title":"Journal of Neuroinflammation"},{"issue":"1","key":"10.1016\/bs.ai.2026.06.003_bib95","doi-asserted-by":"crossref","DOI":"10.1038\/s41420-022-00823-x","article-title":"MicroRNA-181a-2-3p shuttled by mesenchymal stem cell-secreted extracellular vesicles inhibits oxidative stress in Parkinson\u2019s disease by inhibiting EGR1 and NOX4","volume":"8","author":"Ma","year":"2022","journal-title":"Cell Death Discovery"},{"issue":"Pt 10","key":"10.1016\/bs.ai.2026.06.003_bib96","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1093\/brain\/awv211","article-title":"Baseline and longitudinal grey matter changes in newly diagnosed Parkinson\u2019s disease: ICICLE-PD study","volume":"138","author":"Mak","year":"2015","journal-title":"Brain: A Journal of Neurology"},{"issue":"3","key":"10.1016\/bs.ai.2026.06.003_bib97","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41577-022-00760-x","article-title":"Mitochondrial control of inflammation","volume":"23","author":"Marchi","year":"2023","journal-title":"Nature Reviews. Immunology"},{"key":"10.1016\/bs.ai.2026.06.003_bib98","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.810860","article-title":"The disease modification conundrum in Parkinson\u2019s disease: Failures and hopes","volume":"14","author":"Mari","year":"2022","journal-title":"Frontiers in Aging Neuroscience"},{"issue":"1","key":"10.1016\/bs.ai.2026.06.003_bib99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41514-025-00296-z","article-title":"Age-related nigral downregulation of the Parkinson\u2019s risk factor FAM49B primes human microglia for inflammaging","volume":"12","author":"Martin","year":"2025","journal-title":"Npj Aging"},{"issue":"2","key":"10.1016\/bs.ai.2026.06.003_bib100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/brainsci11020215","article-title":"Cerebrospinal fluid biomarkers of Alzheimer\u2019s disease: Current evidence and future perspectives","volume":"11","author":"McGrowder","year":"2021","journal-title":"Brain Sciences"},{"issue":"1","key":"10.1016\/bs.ai.2026.06.003_bib101","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium","volume":"89","author":"McKeith","year":"2017","journal-title":"Neurology"},{"issue":".1","key":"10.1016\/bs.ai.2026.06.003_bib102","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1016\/S1353-8020(13)70020-8","article-title":"Quantification of \u03b1-synuclein in cerebrospinal fluid: How ideal is this biomarker for Parkinson\u2019s disease?","volume":"20","author":"Mollenhauer","year":"2014","journal-title":"Parkinsonism & Related Disorders"},{"issue":"19","key":"10.1016\/bs.ai.2026.06.003_bib103","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1212\/WNL.0000000000004609","article-title":"Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls","volume":"89","author":"Mollenhauer","year":"2017","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/bs.ai.2026.06.003_bib104","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1212\/WNL.0000000000002651","article-title":"Monitoring of 30 marker candidates in early Parkinson disease as progression markers","volume":"87","author":"Mollenhauer","year":"2016","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/bs.ai.2026.06.003_bib105","doi-asserted-by":"crossref","first-page":"C40","DOI":"10.1152\/ajpcell.00416.2025","article-title":"Role of persistent necroinflammation in chronic tissue remodeling and organ fibrosis","volume":"330","author":"More","year":"2025","journal-title":"American Journal of Physiology. Cell Physiology"},{"issue":"1","key":"10.1016\/bs.ai.2026.06.003_bib106","doi-asserted-by":"crossref","first-page":"7803","DOI":"10.1038\/s41598-019-44173-8","article-title":"Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer\u2019s disease","volume":"9","author":"Morenas-Rodr\u00edguez","year":"2019","journal-title":"Scientific Reports"},{"issue":"4","key":"10.1016\/bs.ai.2026.06.003_bib107","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/jamaneurol.2019.4611","article-title":"Ambroxol for the treatment of patients with Parkinson disease with and without glucocerebrosidase gene mutations: A nonrandomized, noncontrolled trial","volume":"77","author":"Mullin","year":"2020","journal-title":"JAMA Neurology"},{"issue":"4","key":"10.1016\/bs.ai.2026.06.003_bib108","first-page":"422","article-title":"MPTP-induced mouse model of Parkinson\u2019s disease: A promising direction of therapeutic strategies","volume":"21","author":"Mustapha","year":"2021","journal-title":"Bosnian Journal of Basic Medical Sciences"},{"issue":"15","key":"10.1016\/bs.ai.2026.06.003_bib109","first-page":"24","article-title":"An updated review on pharmaceutical properties of gamma-aminobutyric acid","volume":"24","author":"Ngo","year":"2019","journal-title":"Molecules 2019"},{"issue":"4","key":"10.1016\/bs.ai.2026.06.003_bib110","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1212\/01.wnl.0000327823.81237.d1","article-title":"Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset","volume":"72","author":"Nichols","year":"2009","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/bs.ai.2026.06.003_bib111","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.parkreldis.2014.04.005","article-title":"Differentiation of early-stage parkinsonisms using neuromelanin-sensitive magnetic resonance imaging","volume":"20","author":"Ohtsuka","year":"2014","journal-title":"Parkinsonism and Related Disorders"},{"issue":"2","key":"10.1016\/bs.ai.2026.06.003_bib112","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/jnnp.67.2.189","article-title":"(123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson\u2019s disease","volume":"67","author":"Orimo","year":"1999","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"16","key":"10.1016\/bs.ai.2026.06.003_bib113","doi-asserted-by":"crossref","first-page":"6048","DOI":"10.1523\/JNEUROSCI.20-16-06048.2000","article-title":"The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity","volume":"20","author":"Ostrerova-Golts","year":"2000","journal-title":"The Journal of Neuroscience: The Official Journal of the Society for Neuroscience"},{"issue":"4","key":"10.1016\/bs.ai.2026.06.003_bib114","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41591-024-02886-y","article-title":"Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson\u2019s disease","volume":"30","author":"Pagano","year":"2024","journal-title":"Nature Medicine"},{"issue":"20","key":"10.1016\/bs.ai.2026.06.003_bib115","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222011234","article-title":"Dopamine transporter imaging, current status of a potential biomarker: A comprehensive review","volume":"22","author":"Palermo","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"issue":"1","key":"10.1016\/bs.ai.2026.06.003_bib116","doi-asserted-by":"crossref","DOI":"10.1186\/s40035-023-00374-w","article-title":"Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson\u2019s disease","volume":"12","author":"Paslawski","year":"2023","journal-title":"Translational Neurodegeneration"},{"issue":"10","key":"10.1016\/bs.ai.2026.06.003_bib117","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1038\/s43587-023-00478-y","article-title":"DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease","volume":"3","author":"Pereira","year":"2023","journal-title":"Nature Aging"},{"issue":"5","key":"10.1016\/bs.ai.2026.06.003_bib118","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1007\/s00415-023-11607-3","article-title":"White and gray matter alterations in de novo PD patients: Which matter most?","volume":"270","author":"Pietracupa","year":"2023","journal-title":"Journal of Neurology"},{"issue":"6","key":"10.1016\/bs.ai.2026.06.003_bib119","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1002\/glia.23970","article-title":"\u03b1-Synuclein evokes NLRP3 inflammasome-mediated IL-1\u03b2 secretion from primary human microglia","volume":"69","author":"Pike","year":"2021","journal-title":"Glia"},{"issue":"3","key":"10.1016\/bs.ai.2026.06.003_bib120","doi-asserted-by":"crossref","DOI":"10.3390\/ijms27031509","article-title":"Clinical applications of extracellular vesicles: Promises and pitfalls","volume":"27","author":"Primorac","year":"2026","journal-title":"International Journal of Molecular Sciences"},{"issue":"2","key":"10.1016\/bs.ai.2026.06.003_bib121","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.cell.2019.08.053","article-title":"Microglia biology: One century of evolving concepts","volume":"179","author":"Prinz","year":"2019","journal-title":"Cell"},{"issue":"4","key":"10.1016\/bs.ai.2026.06.003_bib122","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1177\/1756285613511507","article-title":"A review of the use of magnetic resonance imaging in Parkinson\u2019s disease","volume":"7","author":"Pyatigorskaya","year":"2014","journal-title":"Therapeutic Advances in Neurological Disorders"},{"issue":"7","key":"10.1016\/bs.ai.2026.06.003_bib123","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.crad.2010.03.011","article-title":"Molecular imaging: Current status and emerging strategies","volume":"65","author":"Pysz","year":"2010","journal-title":"Clinical Radiology"},{"issue":"1","key":"10.1016\/bs.ai.2026.06.003_bib124","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41531-023-00449-5","article-title":"A systematic review and meta-analysis of inflammatory biomarkers in Parkinson\u2019s disease","volume":"9","author":"Qu","year":"2023","journal-title":"Npj Parkinson\u2019s Disease"},{"issue":"10","key":"10.1016\/bs.ai.2026.06.003_bib125","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/ng1884","article-title":"Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase","volume":"38","author":"Ramirez","year":"2006","journal-title":"Nature Genetics"},{"issue":"6","key":"10.1016\/bs.ai.2026.06.003_bib126","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/jnc.15601","article-title":"Plasma \u03b1-synuclein and phosphorylated tau 181 as a diagnostic biomarker panel for de novo Parkinson\u2019s disease","volume":"161","author":"Ren","year":"2022","journal-title":"Journal of Neurochemistry"},{"issue":"4","key":"10.1016\/bs.ai.2026.06.003_bib127","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.celrep.2017.07.004","article-title":"The lifespan and turnover of microglia in the human brain","volume":"20","author":"R\u00e9u","year":"2017","journal-title":"Cell Reports"},{"issue":"4","key":"10.1016\/bs.ai.2026.06.003_bib128","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1007\/s13311-014-0294-x","article-title":"A GCase chaperone improves motor function in a mouse model of synucleinopathy","volume":"11","author":"Richter","year":"2014","journal-title":"Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics"},{"key":"10.1016\/bs.ai.2026.06.003_bib129","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2020.00865","article-title":"The current state-of-the art of LRRK2-based biomarker assay development in Parkinson\u2019s disease","volume":"14","author":"Rideout","year":"2020","journal-title":"Frontiers in Neuroscience"},{"issue":"1","key":"10.1016\/bs.ai.2026.06.003_bib130","doi-asserted-by":"crossref","DOI":"10.1186\/s40035-024-00402-3","article-title":"Emerging role of senescent microglia in brain aging-related neurodegenerative diseases","volume":"13","author":"Rim","year":"2024","journal-title":"Translational Neurodegeneration"},{"issue":"1","key":"10.1016\/bs.ai.2026.06.003_bib131","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00401-020-02160-8","article-title":"Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies","volume":"140","author":"Rossi","year":"2020","journal-title":"Acta Neuropathologica"},{"key":"10.1016\/bs.ai.2026.06.003_bib132","article-title":"Single nuclear RNA sequencing shows altered microglial and astrocytic functions in post-mortem Parkinson\u2019s disease tissue","author":"Roy","year":"2025","journal-title":"BioRxiv"},{"key":"10.1016\/bs.ai.2026.06.003_bib133","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.572976","article-title":"Neuroimaging advances in Parkinson\u2019s disease and atypical Parkinsonian syndromes","volume":"11","author":"Saeed","year":"2020","journal-title":"Frontiers in Neurology"},{"issue":"6","key":"10.1016\/bs.ai.2026.06.003_bib134","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.cell.2016.11.018","article-title":"Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson\u2019s disease","volume":"167","author":"Sampson","year":"2016","journal-title":"Cell"},{"key":"10.1016\/bs.ai.2026.06.003_bib135","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02578","article-title":"OLT1177 (Dapansutrile), a selective NLRP3 inflammasome inhibitor, ameliorates experimental autoimmune encephalomyelitis pathogenesis","volume":"10","author":"S\u00e1nchez-Fern\u00e1ndez","year":"2019","journal-title":"Frontiers in Immunology"},{"issue":"8064","key":"10.1016\/bs.ai.2026.06.003_bib136","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/s41586-025-08700-0","article-title":"Phase I\/II trial of iPS-cell-derived dopaminergic cells for Parkinson\u2019s disease","volume":"641","author":"Sawamoto","year":"2025","journal-title":"Nature"},{"issue":"5","key":"10.1016\/bs.ai.2026.06.003_bib137","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13195-014-0072-3","article-title":"Biomarkers in biological fluids for dementia with Lewy bodies","volume":"6","author":"Schade","year":"2014","journal-title":"Alzheimer\u2019s Research & Therapy"},{"issue":"3","key":"10.1016\/bs.ai.2026.06.003_bib138","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00401-012-0996-2","article-title":"The genetics and neuropathology of Alzheimer\u2019s disease","volume":"124","author":"Schellenberg","year":"2012","journal-title":"Acta Neuropathologica"},{"issue":"11","key":"10.1016\/bs.ai.2026.06.003_bib139","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/mds.27193","article-title":"Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature","volume":"32","author":"Schneider","year":"2017","journal-title":"Movement Disorders"},{"issue":"1","key":"10.1016\/bs.ai.2026.06.003_bib140","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1038\/ncomms5028","article-title":"iPSC-derived neurons from GBA1-associated Parkinson\u2019s disease patients show autophagic defects and impaired calcium homeostasis","volume":"5","author":"Sch\u00f6ndorf","year":"2014","journal-title":"Nature Communications"},{"issue":"11","key":"10.1016\/bs.ai.2026.06.003_bib141","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1007\/s00702-025-02942-y","article-title":"Neuroimaging in advanced Parkinson\u2019s disease: Insights into pathophysiology, biomarkers, and personalized therapies","volume":"132","author":"Schr\u00f6ter","year":"2025","journal-title":"Journal of Neural Transmission (Vienna, Austria: 1996)"},{"issue":"1","key":"10.1016\/bs.ai.2026.06.003_bib142","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41531-024-00744-9","article-title":"Lack of genetic evidence for NLRP3 inflammasome involvement in Parkinson\u2019s disease pathogenesis","volume":"10","author":"Senkevich","year":"2024","journal-title":"Npj Parkinson\u2019s Disease"},{"issue":"2","key":"10.1016\/bs.ai.2026.06.003_bib143","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/ana.26410","article-title":"Plasma MIA, CRP, and albumin predict cognitive decline in Parkinson\u2019s disease","volume":"92","author":"Shen","year":"2022","journal-title":"Annals of Neurology"},{"issue":"3","key":"10.1016\/bs.ai.2026.06.003_bib144","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/ana.22311","article-title":"Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression","volume":"69","author":"Shi","year":"2011","journal-title":"Annals of Neurology"},{"issue":"5","key":"10.1016\/bs.ai.2026.06.003_bib145","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S1474-4422(23)00109-6","article-title":"Assessment of heterogeneity among participants in the Parkinson\u2019s progression markers initiative cohort using \u03b1-synuclein seed amplification: A cross-sectional study","volume":"22","author":"Siderowf","year":"2023","journal-title":"The Lancet Neurology"},{"issue":"17","key":"10.1016\/bs.ai.2026.06.003_bib146","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","article-title":"Multicenter analysis of glucocerebrosidase mutations in Parkinson\u2019s disease","volume":"361","author":"Sidransky","year":"2009","journal-title":"The New England Journal of Medicine"},{"issue":"1","key":"10.1016\/bs.ai.2026.06.003_bib147","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-024-03629-9","article-title":"Study protocol of the GRoningen early-PD Ambroxol treatment (GREAT) trial: a randomized, double-blind, placebo-controlled, single center trial with ambroxol in Parkinson patients with a GBA mutation","volume":"24","author":"Siemeling","year":"2024","journal-title":"BMC Neurology"},{"issue":"2","key":"10.1016\/bs.ai.2026.06.003_bib148","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S1474-4422(23)00405-2","article-title":"A biological definition of neuronal \u03b1-synuclein disease: towards an integrated staging system for research","volume":"23","author":"Simuni","year":"2024","journal-title":"The Lancet Neurology"},{"issue":"5","key":"10.1016\/bs.ai.2026.06.003_bib149","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/mds.27361","article-title":"Longitudinal change of clinical and biological measures in early Parkinson\u2019s disease: Parkinson\u2019s progression markers initiative cohort","volume":"33","author":"Simuni","year":"2018","journal-title":"Movement Disorders: Official Journal of the Movement Disorder Society"},{"issue":"10","key":"10.1016\/bs.ai.2026.06.003_bib150","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.tins.2023.07.009","article-title":"Inflammasome assembly in neurodegenerative diseases","volume":"46","author":"Singh","year":"2023","journal-title":"Trends in Neurosciences"},{"issue":"3","key":"10.1016\/bs.ai.2026.06.003_bib151","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1093\/brain\/awab446","article-title":"Single-cell sequencing of human midbrain reveals glial activation and a Parkinson-specific neuronal state","volume":"145","author":"Smajic","year":"2022","journal-title":"Brain: A Journal of Neurology"},{"issue":"MAY","key":"10.1016\/bs.ai.2026.06.003_bib152","article-title":"Pharmacological modulation of functional phenotypes of microglia in neurodegenerative diseases","volume":"9","author":"Song","year":"2017","journal-title":"Frontiers in Aging Neuroscience"},{"issue":"5","key":"10.1016\/bs.ai.2026.06.003_bib153","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2174\/156720510791383796","article-title":"The cerebrospinal fluid amyloid \u03b242\/40 ratio in the differentiation of Alzheimers disease from non-Alzheimers dementia","volume":"7","author":"Spies","year":"2010","journal-title":"Current Alzheimer Research"},{"issue":"1","key":"10.1016\/bs.ai.2026.06.003_bib154","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40478-015-0185-3","article-title":"Phosphorylated \u03b1-synuclein in Parkinson\u2019s disease: Correlation depends on disease severity","volume":"3","author":"Stewart","year":"2015","journal-title":"Acta Neuropathologica Communications"},{"key":"10.1016\/bs.ai.2026.06.003_bib155","article-title":"Intrastriatal gradient analyses of 18F-FDOPA PET scans for differentiation of Parkinsonian disorders","volume":"25","author":"Stormezand","year":"2020","journal-title":"NeuroImage: Clinical"},{"issue":"11","key":"10.1016\/bs.ai.2026.06.003_bib156","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1002\/mds.28639","article-title":"\u03b1-Synuclein in plasma-derived extracellular vesicles is a potential biomarker of Parkinson\u2019s disease","volume":"36","author":"Stuendl","year":"2021","journal-title":"Movement Disorders"},{"issue":"1","key":"10.1016\/bs.ai.2026.06.003_bib157","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41531-018-0047-3","article-title":"Neuromelanin detection by magnetic resonance imaging (MRI) and its promise as a biomarker for Parkinson\u2019s disease","volume":"4","author":"Sulzer","year":"2018","journal-title":"Npj Parkinson\u2019s Disease"},{"issue":"3","key":"10.1016\/bs.ai.2026.06.003_bib158","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/mds.27929","article-title":"Quantitative evaluation of iron content in idiopathic rapid eye movement sleep behavior disorder","volume":"35","author":"Sun","year":"2020","journal-title":"Movement Disorders: Official Journal of the Movement Disorder Society"},{"issue":"8064","key":"10.1016\/bs.ai.2026.06.003_bib159","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/s41586-025-08845-y","article-title":"Phase I trial of hES\u00a0cell-derived dopaminergic neurons for Parkinson\u2019s disease","volume":"641","author":"Tabar","year":"2025","journal-title":"Nature"},{"key":"10.1016\/bs.ai.2026.06.003_bib160","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.neubiorev.2021.11.044","article-title":"Subthalamic burst firing: A pathophysiological target in Parkinson\u2019s disease","volume":"132","author":"Tai","year":"2022","journal-title":"Neuroscience and Biobehavioral Reviews"},{"key":"10.1016\/bs.ai.2026.06.003_bib161","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2025.107833","article-title":"Allogenic transplantation therapy of iPS cell-derived dopamine progenitors for Parkinson\u2019s disease \u2013Current status of the Kyoto trial and future perspectives","volume":"135","author":"Takahashi","year":"2025","journal-title":"Parkinsonism and Related Disorders"},{"issue":"6","key":"10.1016\/bs.ai.2026.06.003_bib162","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41582-020-0344-4","article-title":"Parkinson disease and the immune system - associations, mechanisms and therapeutics","volume":"16","author":"Tan","year":"2020","journal-title":"Nature Reviews. Neurology"},{"issue":"1","key":"10.1016\/bs.ai.2026.06.003_bib163","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41531-023-00447-7","article-title":"Plasma GFAP in Parkinson\u2019s disease with cognitive impairment and its potential to predict conversion to dementia","volume":"9","author":"Tang","year":"2023","journal-title":"Npj Parkinson\u2019s Disease"},{"issue":"1","key":"10.1016\/bs.ai.2026.06.003_bib164","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41746-025-01572-8","article-title":"Exploratory digital outcome measures of motor sign progression in Parkinson\u2019s disease patients treated with prasinezumab","volume":"8","author":"Taylor","year":"2025","journal-title":"Npj Digital Medicine"},{"key":"10.1016\/bs.ai.2026.06.003_bib165","doi-asserted-by":"crossref","DOI":"10.1016\/j.conb.2025.103164","article-title":"The challenges of experimental pharmacology in identifying novel treatments for Parkinson\u2019s disease","volume":"97","author":"Teil","year":"2026","journal-title":"Current Opinion in Neurobiology"},{"issue":"2","key":"10.1016\/bs.ai.2026.06.003_bib166","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/jnc.15780","article-title":"The relationship between serum neurofilament light chain and glial fibrillary acidic protein with the REM sleep behavior disorder subtype of Parkinson\u2019s disease","volume":"165","author":"Teng","year":"2023","journal-title":"Journal of Neurochemistry"},{"issue":"6411","key":"10.1016\/bs.ai.2026.06.003_bib167","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1126\/science.aat0474","article-title":"Microglia and early brain development: An intimate journey","volume":"362","author":"Thion","year":"2018","journal-title":"Science (New York, N. Y.)"},{"issue":"4","key":"10.1016\/bs.ai.2026.06.003_bib168","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1136\/jnnp-2019-322042","article-title":"Brain iron deposition is linked with cognitive severity in Parkinson\u2019s disease","volume":"91","author":"Thomas","year":"2020","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"1","key":"10.1016\/bs.ai.2026.06.003_bib169","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40035-019-0155-y","article-title":"Erythrocytic \u03b1-synuclein as a potential biomarker for Parkinson\u2019s disease","volume":"8","author":"Tian","year":"2019","journal-title":"Translational Neurodegeneration"},{"key":"10.1016\/bs.ai.2026.06.003_bib170","article-title":"Unveiling MRI markers for Parkinson\u2019s disease: GABAergic dysfunction and cortical changes","volume":"43","author":"Tian","year":"2024","journal-title":"NeuroImage: Clinical"},{"issue":"1","key":"10.1016\/bs.ai.2026.06.003_bib171","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/RLU.0000000000001885","article-title":"Semiquantitative analysis of dopamine transporter scans in patients with Parkinson disease","volume":"43","author":"Tinaz","year":"2018","journal-title":"Clinical Nuclear Medicine"},{"issue":"9","key":"10.1016\/bs.ai.2026.06.003_bib172","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s00702-022-02498-1","article-title":"Blood-based biomarker in Parkinson\u2019s disease: Potential for future applications in clinical research and practice","volume":"129","author":"T\u00f6nges","year":"2022","journal-title":"Journal of Neural Transmission"},{"key":"10.1016\/bs.ai.2026.06.003_bib173","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2025.108009","article-title":"Diagnostic performance of T1-Weighted MRI gray matter biomarkers in Parkinson\u2019s disease: A systematic review and meta-analysis","volume":"140","author":"Torres-Parga","year":"2025","journal-title":"Parkinsonism and Related Disorders"},{"issue":"1","key":"10.1016\/bs.ai.2026.06.003_bib174","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s10286-011-0135-5","article-title":"MIBG scintigraphy in differential diagnosis of Parkinsonism: A meta-analysis","volume":"22","author":"Treglia","year":"2012","journal-title":"Clinical Autonomic Research: Official Journal of the Clinical Autonomic Research Society"},{"issue":"7","key":"10.1016\/bs.ai.2026.06.003_bib175","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1002\/mds.30193","article-title":"Intraputaminal delivery of adeno-associated virus serotype 2-Glial cell line-derived neurotrophic factor in mild or moderate Parkinson\u2019s disease","volume":"40","author":"Van Laar","year":"2025","journal-title":"Movement Disorders: Official Journal of the Movement Disorder Society"},{"issue":"7","key":"10.1016\/bs.ai.2026.06.003_bib176","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1474-4422(21)00061-2","article-title":"Progress towards therapies for disease modification in Parkinson\u2019s disease","volume":"20","author":"Vijiaratnam","year":"2021","journal-title":"The Lancet Neurology"},{"issue":"1","key":"10.1016\/bs.ai.2026.06.003_bib177","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.neuron.2011.08.033","article-title":"Exogenous \u03b1-synuclein fibrils induce lewy body pathology leading to synaptic dysfunction and neuron death","volume":"72","author":"Volpicelli-Daley","year":"2011","journal-title":"Neuron"},{"issue":"5","key":"10.1016\/bs.ai.2026.06.003_bib178","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/jnc.14698","article-title":"Clinical and neuropathological differences between Parkinson\u2019s disease, Parkinson\u2019s disease dementia and dementia with Lewy bodies \u2013 current issues and future directions","volume":"150","author":"Walker","year":"2019","journal-title":"Journal of Neurochemistry"},{"issue":"6","key":"10.1016\/bs.ai.2026.06.003_bib179","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1042\/BST20180463","article-title":"LRRK2 regulation of immune-pathways and inflammatory disease","volume":"47","author":"Wallings","year":"2019","journal-title":"Biochemical Society Transactions"},{"key":"10.1016\/bs.ai.2026.06.003_bib180","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.neubiorev.2015.09.007","article-title":"Neuroimaging of Parkinson\u2019s disease: Expanding views","volume":"59","author":"Weingarten","year":"2015","journal-title":"Neuroscience and Biobehavioral Reviews"},{"issue":"7","key":"10.1016\/bs.ai.2026.06.003_bib181","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1093\/brain\/awab122","article-title":"Reactive microglia enhance the transmission of exosomal \u03b1-synuclein via toll-like receptor 2","volume":"144","author":"Xia","year":"2021","journal-title":"Brain: A Journal of Neurology"},{"issue":"1","key":"10.1016\/bs.ai.2026.06.003_bib182","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41531-025-00886-4","article-title":"Prasinezumab slows motor progression in Parkinsons disease: Beyond the clinical data","volume":"11","author":"Xiao","year":"2025","journal-title":"Npj Parkinson\u2019s Disease"},{"issue":"4","key":"10.1016\/bs.ai.2026.06.003_bib183","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41423-025-01275-w","article-title":"NLRP3 inflammasome in neuroinflammation and central nervous system diseases","volume":"22","author":"Xu","year":"2025","journal-title":"Cellular & Molecular Immunology"},{"issue":"7\u20138","key":"10.1016\/bs.ai.2026.06.003_bib184","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1080\/21678421.2025.2515900","article-title":"A phase 2, proof-of-concept, placebo-controlled, randomized, multicenter, double-blind study to evaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of Usnoflast (ZYIL1) in patients with amyotrophic lateral sclerosis","volume":"26","author":"Yeole","year":"2025","journal-title":"Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration"},{"issue":"2","key":"10.1016\/bs.ai.2026.06.003_bib185","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/00006231-199802000-00007","article-title":"Decreased myocardial accumulation of 123I-meta-iodobenzyl guanidine in Parkinson\u2019s disease","volume":"19","author":"Yoshita","year":"1998","journal-title":"Nuclear Medicine Communications"},{"key":"10.1016\/bs.ai.2026.06.003_bib186","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.expneurol.2018.01.009","article-title":"Early activation of Egr-1 promotes neuroinflammation and dopaminergic neurodegeneration in an experimental model of Parkinson\u2019s disease","volume":"302","author":"Yu","year":"2018","journal-title":"Experimental Neurology"},{"key":"10.1016\/bs.ai.2026.06.003_bib187","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2026.120932","article-title":"Small extracellular vesicles as emerging biomarkers and therapeutic targets in neurodegenerative diseases","volume":"587","author":"Zafarjonovna","year":"2026","journal-title":"Clinica Chimica Acta"},{"issue":"1","key":"10.1016\/bs.ai.2026.06.003_bib188","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1038\/s41598-022-05227-6","article-title":"Early downregulation of hsa-miR-144-3p in serum from drug-na\u00efve Parkinson\u2019s disease patients","volume":"12","author":"Zago","year":"2022","journal-title":"Scientific Reports"},{"issue":"3","key":"10.1016\/bs.ai.2026.06.003_bib189","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcae130","article-title":"Neuroimaging and plasma evidence of early white matter loss in Parkinson\u2019s disease with poor outcomes","volume":"6","author":"Zarkali","year":"2024","journal-title":"Brain Communications"},{"issue":"5","key":"10.1016\/bs.ai.2026.06.003_bib190","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/mds.28477","article-title":"Visual dysfunction predicts cognitive impairment and white matter degeneration in Parkinson\u2019s disease","volume":"36","author":"Zarkali","year":"2021","journal-title":"Movement Disorders: Official Journal of the Movement Disorder Society"},{"issue":"1","key":"10.1016\/bs.ai.2026.06.003_bib191","doi-asserted-by":"crossref","first-page":"5661","DOI":"10.1038\/s41467-024-49949-9","article-title":"Neuroimaging and fluid biomarkers in Parkinson\u2019s disease in an era of targeted interventions","volume":"15","author":"Zarkali","year":"2024","journal-title":"Nature Communications"},{"issue":"7\u20139","key":"10.1016\/bs.ai.2026.06.003_bib192","article-title":"Cytokine-microglia interactions in neuroinflammation: Mechanisms, disease dynamics, and therapeutic strategies","volume":"44","author":"Zhang","year":"2026","journal-title":"Antioxidants & Redox Signaling"},{"issue":"7","key":"10.1016\/bs.ai.2026.06.003_bib193","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.nrl.2022.03.002","article-title":"Circulating microRNAs as potential biomarkers for the diagnosis of Parkinson\u2019s disease: A meta-analysis","volume":"39","author":"Zhang","year":"2024","journal-title":"Neurolog\u00eda"},{"issue":"1","key":"10.1016\/bs.ai.2026.06.003_bib194","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41531-024-00846-4","article-title":"Microglia depletion reduces neurodegeneration and remodels extracellular matrix in a mouse Parkinson\u2019s disease model triggered by \u03b1-synuclein overexpression","volume":"11","author":"Zhang","year":"2025","journal-title":"Npj Parkinson\u2019s Disease"},{"issue":"12","key":"10.1016\/bs.ai.2026.06.003_bib195","doi-asserted-by":"crossref","DOI":"10.3390\/cells11121933","article-title":"Using extracellular vesicles released by GDNF-transfected macrophages for therapy of Parkinson disease","volume":"11","author":"Zhao","year":"2022","journal-title":"Cells"},{"key":"10.1016\/bs.ai.2026.06.003_bib196","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.parkreldis.2022.06.001","article-title":"Plasma and serum alpha-synuclein as a biomarker in Parkinson\u2019s disease: A meta-analysis","volume":"99","author":"Zubelzu","year":"2022","journal-title":"Parkinsonism and Related Disorders"},{"issue":"1","key":"10.1016\/bs.ai.2026.06.003_bib197","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/iub.2654","article-title":"Neuromelanins in brain aging and Parkinson\u2019s disease: Synthesis, structure, neuroinflammatory, and neurodegenerative role","volume":"75","author":"Zucca","year":"2023","journal-title":"IUBMB Life"},{"key":"10.1016\/bs.ai.2026.06.003_bib198","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.pneurobio.2015.09.012","article-title":"Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson\u2019s disease","volume":"155","author":"Zucca","year":"2017","journal-title":"Progress in Neurobiology"}],"container-title":["Advances in Immunology","Microglial Advances in Neurodegenerative Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065277626000349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065277626000349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T17:00:56Z","timestamp":1787331656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065277626000349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9780443470547"],"references-count":198,"URL":"https:\/\/doi.org\/10.1016\/bs.ai.2026.06.003","relation":{},"ISSN":["0065-2776"],"issn-type":[{"value":"0065-2776","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]}}}